Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%

It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines.

Saturday at the World Conference on Lung Cancer’s virtual presidential symposium, Bristol Myers unveiled phase 3 data showing the pair decreased the risk of death among previously untreated mesothelioma patients by 26%, helping them live a median four months longer than those in the study’s chemo arm.